New Zealand medical device regulatory framework
New Zealand is different from many medical device markets because most devices are not approved by Medsafe before supply. Instead, New Zealand relies on sponsor notification through the Web Assisted Notification of Devices database, known as WAND, plus sponsor-held evidence and post-market oversight.
This lighter pathway can be commercially attractive, but it should not be treated as a no-regulation market. The New Zealand sponsor must understand the device, notify WAND within the required timeframe, keep evidence that the product is safe for its intended purpose, maintain product and supplier records, and support complaint, adverse event, recall, and change obligations.
For foreign manufacturers, the first decision is therefore operational: who is the New Zealand sponsor, what evidence will that sponsor hold, and how will post-market responsibilities be managed after launch?
Authority and WAND notification
Medsafe is New Zealand's medicines and medical devices safety authority. The WAND database records medical devices supplied in New Zealand. WAND notification is important, but it is not the same as pre-market approval, certification, or product endorsement by Medsafe.
The sponsor is the New Zealand person or company that imports or supplies the device. The sponsor must notify WAND within the required timeframe after becoming the sponsor of the device, described in Medsafe sponsor guidance as 30 working days. The sponsor also needs to maintain information about the device, manufacturer, classification, GMDN, intended purpose, and supply model. There is no government fee for WAND notification and no renewal cycle: a WAND entry stays active until the sponsor ceases supply, but the sponsor must correct or remove outdated information within 10 working days.
Because the WAND entry does not prove regulatory approval, manufacturers should avoid promotional language suggesting that a device is "approved by Medsafe" merely because it has been notified. The safer framing is that the device has been notified in WAND by the New Zealand sponsor.
Classification and evidence expectations
New Zealand WAND notification requires enough product information to identify the device and support the sponsor's obligations. Manufacturers should confirm the product's device status, intended purpose, GMDN selection, risk classification, manufacturer details, and product family structure before notification.
Even where Medsafe does not perform pre-market review, the sponsor should hold evidence that the product is safe for its intended purpose. That evidence may include conformity assessment documents, ISO 13485 certificates, EU CE or MDR/IVDR evidence, Australian TGA evidence, US FDA evidence, test reports, risk management, clinical or performance evidence, labeling, IFU, and post-market procedures. The right package depends on device type and risk.
For manufacturers selling in both Australia and New Zealand, there can be practical reuse of technical documentation and quality evidence. Reuse is helpful, but the New Zealand sponsor still needs a New Zealand-specific WAND record, product information, and post-market responsibility model.
Sponsor and labeling responsibilities
The sponsor role should be selected carefully. It may be a distributor, importer, affiliate, or regulatory partner. The sponsor's responsibilities can affect who controls WAND entries, who receives Medsafe communications, who holds evidence, who manages complaints, and who coordinates recalls.
Labeling should be reviewed before supply to make sure the product identity, intended use, warnings, storage conditions, batch or serial controls, manufacturer information, and local sponsor or importer details are consistent with the device being notified. If a device is supplied with digital labeling, software instructions, or online IFU content, those materials should be included in the evidence review.
Post-market obligations
Post-market control is the center of the New Zealand system. Sponsors and manufacturers should maintain procedures for complaints, adverse events, field safety corrective actions, recalls, distribution records, changes, and regulator communications. Global complaint handling should be mapped to New Zealand escalation rules so that local obligations are not missed.
Changes can also affect WAND information. Product name changes, manufacturer changes, model changes, intended-purpose changes, sponsor changes, or supply model changes should be reviewed before implementation. If the product is software-driven, update governance should include regulatory impact assessment for changes to intended use, algorithm behavior, cybersecurity, performance, or labeling.
Practical launch checklist
A practical New Zealand launch plan should include seven workstreams:
- Confirm medical-device status, intended purpose, classification, and GMDN selection.
- Select the New Zealand sponsor and define who owns WAND notification and maintenance.
- Prepare WAND product, manufacturer, model, classification, and sponsor information.
- Confirm that the sponsor holds adequate technical, quality, labeling, and safety evidence.
- Review labeling, IFU, sponsor/importer details, software information, and product claims.
- Build complaint, adverse event, recall, distribution-record, and change-control procedures.
- Coordinate New Zealand planning with Australia, Singapore, and other Asia Pacific launches where evidence can be reused.
Pure Global supports manufacturers with New Zealand WAND notification planning, sponsor-role coordination, evidence review, labeling checks, pricing visibility, and post-market compliance.
